Send us Fan Mail

Editor-in-Chief, Robert Amdur, MD, reviews the evidence for treating Low-Intermediate Risk prostate cancer with Ultra Hypofractionated SBRT. This discussion was stimulated by a paper published in the November/December 2023 issue of PRO titled "Long-Term Outcomes of a Prospective Study on Highly Hypofractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer for 3 Weeks" with PMID 37414247. However, the majority of the podcast will focus on data supporting 5 Fraction SBRT, including the most recent report from the PACE-B trial (Abstract only from the 2023 ASTRO annual Meeting).
Additional Article:
Stereotactic Body Radiation Therapy: A Radiosurgery Society Guide to the Treatment of Localized Prostate Cancer Illustrated by Challenging Cases